Hostname: page-component-745bb68f8f-b95js Total loading time: 0 Render date: 2025-02-10T23:47:55.376Z Has data issue: false hasContentIssue false

Osteopontin in macrophage function

Published online by Cambridge University Press:  26 April 2011

Susan R. Rittling
Affiliation:
The Forsyth Institute, 245 First St, Cambridge, MA 02142, USA. E-mail: srittling@forsyth.org
Rights & Permissions [Opens in a new window]

Abstract

The secreted phosphorylated protein osteopontin (OPN) is expressed in a variety of tissues and bodily fluids, and is associated with pathologies including tissue injury, infection, autoimmune disease and cancer. Macrophages are ubiquitous, heterogeneous cells that mediate aspects of cell and tissue damage in all these pathologies. Here, the role of OPN in macrophage function is reviewed. OPN is expressed in macrophage cells in multiple pathologies, and the regulation of its expression in these cells has been described in vitro. The protein has been implicated in multiple functions of macrophages, including cytokine expression, expression of inducible nitric oxide synthase, phagocytosis and migration. Indeed, the role of OPN in cells of the macrophage lineage might underlie its physiological role in many pathologies. However, there are numerous instances where the published literature is inconsistent, especially in terms of OPN function in vitro. Although the heterogeneity of OPN and its receptors, or of macrophages themselves, might underlie some of these inconsistencies, it is important to understand the role of OPN in macrophage biology in order to exploit its function therapeutically.

Type
Review Article
Copyright
Copyright © Cambridge University Press 2011

Osteopontin (OPN; encoded by the gene SPP1) is a secreted phosphorylated protein originally identified in cancer cells (Ref. Reference Senger1) and in bone (Ref. Reference Oldberg, Franzen and Heinegard2). It is widely expressed in epithelial cells (Ref. Reference Brown3), is a major noncollagenous protein of bone, and is found in most body fluids including milk, blood and urine (Ref. Reference Rittling and Fantuzzi4). It is also made by several types of cells in the immune system, including T cells, where it was originally identified as an early T-cell activation (ETA-1) gene (Ref. Reference Weber and Cantor5), and in macrophages, as described in detail below. It is overexpressed in a wide range of human cancers, and its expression is correlated with poorer prognosis (Ref. Reference Rittling and Chambers6). This might be related to its ability to stimulate migration of many cell types (Ref. Reference Ramaiah and Rittling7). It binds strongly to hydroxyapatite and regulates ectopic calcium deposition in vivo (Ref. Reference Giachelli8).

There are two well-characterised cell-binding sites on OPN (Fig. 1). The RGD sequence binds αv (ITGAV) integrins, including αvβ3, αvβ5 and αvβ1: all these integrins bind OPN with similar affinity (Refs Reference Hu13, Reference Hu, Hoyer and Smith14). The adjacent SVVYGLR sequence in human OPN (SLAYGLR in mouse) is a ligand for α4β1 and α9β1, with the latter binding only the thrombin-cleaved form of OPN with high affinity (Refs Reference Bayless15, Reference Barry16, Reference Yokosaki17). Recently, additional cell-binding sequences have been described that are distinct from these two integrin-binding sequences, although their ligands on cells are still unknown (Refs Reference Cao11, Reference Zheng12). OPN has also been reported to bind to several other integrins, including α5β1 (Ref. Reference Barry18), αvβ6 (Ref. Reference Yokosaki19) and α8β1(Ref. Reference Denda, Reichardt and Müller20): all these interactions are disrupted by RGD peptides, although in the case of α5β1 and αvβ6, upstream amino acid residues affect binding. Recently, OPN has been shown to bind the αxβ2 integrin through a less specific acidic protein interaction that is not localised to a specific set of amino acids (Ref. Reference Schack21). How many of these interactions are physiologically relevant, and in what contexts, is still not clear and is an area that requires further investigation. OPN has also been described as a ligand for CD44 (Ref. Reference Weber22), although it appears that only a limited number of isoforms of this highly variable family of molecules can bind OPN (Ref. Reference Smith23), and it has been suggested that this interaction might be indirect, mediated through β1 integrins (Ref. Reference Katagiri24). The CD44-binding sequence has been variously reported to be in the C-terminal half (Ref. Reference Weber25) and at the N-terminus (Ref. Reference Jain26), so the specificity of this interaction remains unclear.

Figure 1. Key features of mouse osteopontin protein. The unstructured nature of the molecule is indicated by the blue line. The central integrin-binding sequences of mouse osteopontin are indicated: the RGD sequence is underlined in teal, and the SLAYGLR sequence is depicted in purple. The specific integrins that bind to each of these two sequences are indicated. Other features of the molecule are identified: heparin-binding sequences and the poly-Asp sequence that mediates binding to hydroxyapatite (Ref. Reference Scatena, Liaw and Giachelli9); O-glycosylation sites and a subset of phosphorylation sites (Ref. Reference Christensen10); sites of cleavage by thrombin and matrix metalloproteinase (MMP); and recently identified N-terminal sequences involved in lymphocyte binding (Ref. Reference Cao11) and induction of chemokine expression (Ref. Reference Zheng12). The binding sequence mediating CD44 interaction is controversial (see text).

Because OPN binds to many integrins as well as possibly to CD44, it has many characteristics of an adhesive protein. It is found in a soluble form in some tissues, which is consistent with its ability to stimulate migration (Ref. Reference Rittling27). It is variably phosphorylated, with the highest level of phosphates found in milk and bone OPN, and the lowest in the protein made by tumour cells (Ref. Reference Christensen10). It is a substrate for several proteases that regulate its integrin-binding affinity (Refs Reference Christensen28, Reference Agnihotri29, Reference Sharif30). In addition, an intracellular form of OPN has been identified in fibroblasts, macrophages and dendritic cells (Refs Reference Zohar31, Reference Zhu32, Reference Cantor and Shinohara33, Reference Inoue34), which might have distinct functions from the secreted protein.

Mice lacking OPN are healthy and normal in the absence of pathology (Refs Reference Rittling35, Reference Liaw36). However, the response of OPN-deficient mice to a variety of pathologies, including various forms of tissue injury, inflammation, infection and autoimmune disorders, is quite different from that of wild-type (WT) mice (Ref. Reference Lund, Giachelli and Scatena37): OPN-deficient mice are protected from some autoimmune disorders and inflammatory conditions, but are more susceptible to some infections (Ref. Reference Rittling and Fantuzzi4). Many of these pathologies are affected by macrophage functions, and this ubiquitous and variable cell type both expresses and responds to OPN. Given the importance of macrophages in pathology, and the frequent identification of OPN as a protein expressed by activated macrophages, it is likely that OPN has an important role in macrophage function, and thereby in the processes of inflammation and the innate and adaptive immune responses. This article reviews the expression of OPN in macrophages and summarises the reported effects of OPN on macrophage function. OPN is also expressed in, and regulates the function of, the closely related cell types osteoclasts and dendritic cells, but the role of OPN in these cell types, as well as general effects of OPN, are not covered here. Several excellent recent reviews have described the functions of OPN in other systems (Refs Reference Scatena, Liaw and Giachelli9, Reference Cantor and Shinohara33, Reference Wang and Denhardt38, Reference Buback39, Reference Bellahcene40).

OPN expression in monocytes and macrophages

In vitro

OPN is expressed at a low level in monocytes, the circulating macrophage precursor cells, and is induced during their differentiation into macrophages. This has been demonstrated in vitro, where treatment of the human monocytic cell lines HL-60 and THP-1 with phorbol myristate acetate (PMA) results in large increases in OPN expression (Refs Reference Atkins41, Reference Oyama42, Reference Suzuki43). In THP-1 monocytes, PMA, tumour necrosis factor (TNF-α/TNF), interleukin (IL)-6 and oxidised low-density lipoprotein (oxLDL) all induce OPN expression, but PMA is by far the strongest inducer (PMA, 3000-fold; TNF, 80-fold; IL-6, threefold; oxLDL, twofold). Antagonists of the nuclear receptor PPARG (peroxisome proliferator-activated receptor γ) inhibit OPN expression induced by all these compounds and even reduce basal levels (Ref. Reference Oyama42). In HL-60 cells, other inducers of differentiation do not increase OPN expression (Ref. Reference Atkins, Simpson and Somerman44). Mouse macrophages (RAW264.7 or peritoneal) are less sensitive to PMA, showing only a fourfold increase in OPN expression (Ref. Reference Nakamachi45), but these cells already express very high levels of OPN.

Several cytokines have been shown to increase OPN expression in monocytes and macrophages: interferon γ (IFN-γ/IFNG) stimulates expression in THP-1 cells (Ref. Reference Li, O'Regan and Berman46); TNF increases OPN expression in the aHINS-B3 macrophage cell line (Ref. Reference Miyazaki47) [but not in the P388D cell line (Ref. Reference Wuthrich48)]; and expression is induced by IL-10 in human blood monocytes, an effect that is suppressed by IL-4 and IL-13 (Ref. Reference Konno49). IL-6 is implicated in the adipocyte-induced induction of OPN expression in U937 cells in coculture experiments (Ref. Reference Samuvel50). In thioglycollate-elicited peritoneal macrophages, OPN mRNA levels are induced by OPN itself (Ref. Reference Rollo and Denhardt51). Coculture of human blood monocytes with tumour cells secreting colony-stimulating factor 1 (CSF1) induces OPN, suggesting that CSF1 can also regulate OPN expression in these cells (Ref. Reference Solinas52).

In RAW264.7 macrophage-like cells, OPN expression is increased after treatment with TNF, IL-1β or IFN-γ, in a mechanism dependent on the transcription factor AP-1, and this induction is inhibited by SERPINE1 ligands (Ref. Reference Ogawa53). Induction of expression by IL-1β, IFN-γ or lipopolysaccharide (LPS) is dependent on nitric oxide (NO) (Refs Reference Guo54, Reference Gao55, Reference Takahashi56) because blocking NO function with the arginine analogue l-nitroarginine methyl ester prevents the induction of OPN, but NO alone is not sufficient for OPN induction (Ref. Reference Guo54). The mechanism of NO regulation of OPN involves heterogeneous nuclear ribonucleoprotein A/B (HNRNPA/B), which acts as a repressor of OPN transcription: S-nitrosylation of this protein through NO relieves this repression to increase OPN transcription (Ref. Reference Gao55). In the case of LPS, a further increase in OPN expression results from increased expression of HNRNPU, which binds to the same promoter sequence on OPN vacated by HNRNPA/B (Ref. Reference Gao57). Interestingly, recent results suggest that secretion of OPN is not regulated by LPS in RAW264.7 and mouse peritoneal macrophages: rather, intracellular OPN levels are induced several-fold (Ref. Reference Zhao58), suggesting the LPS exerts translational as well as transcriptional control on OPN expression. The analysis of OPN expression in transformed cell lines (such as RAW264.7) must be interpreted with caution, however, because OPN is often upregulated as a result of cellular transformation (Ref. Reference Rittling and Chambers6). Accordingly, although OPN was identified as a constitutively expressed gene in human monocytes differentiated in vitro, its expression was not increased by LPS in these cells, as determined by array analysis (Ref. Reference Nares59). Thus, further experiments are required to understand the regulation of OPN expression by LPS, in different macrophage subtypes and in different species.

Nevertheless, OPN expression has been shown to be regulated during microbial infection in human monocytes and macrophages. Its expression is induced in CD14+ peripheral blood mononuclear cells (PBMCs; CD14+ cells are monocytes) after coculture with microorganisms such as the opportunistic fungal pathogen Penicillium marneffei, in a CSF2-dependent manner (Ref. Reference Koguchi60). However, macrophages differentiated with CSF1 and cocultured with BCG (Bacillus Calmette–Guérin, an attenuated form of Mycobacterium bovis) express significantly more OPN than similar cells differentiated with CSF2 (Ref. Reference Khajoee61), implicating CSF1 in the mechanism of regulation of OPN expression in macrophages. Kupffer cells isolated from normal rats do not express OPN, but the protein is expressed in these cells isolated from rats 7 days after Propionibacterium acnes infection (Ref. Reference Wang62). OPN is induced in THP-1 cells after infection with M. tuberculosis (Ref. Reference Ragno63), and in alveolar macrophages of mice infected with M. tuberculosis (Ref. Reference van der Windt64).

Together, these results demonstrate that OPN expression is part of the response of macrophages to a variety of stimuli, suggesting that this expression is important in macrophage function (Fig. 2).

Figure 2. Summary of osteopontin regulation in and effects on monocytes and macrophages. Substances that induce osteopontin (OPN) expression in monocytes (left) and macrophages (right) are indicated in the blue boxes. Phorbol myristate acetate (PMA) induces both OPN expression and differentiation of monocytes into macrophages. The presence of intracellular OPN in macrophages is indicated. Some effects of OPN on macrophage function are listed in the pink box; although these are depicted as resulting from OPN secreted by macrophages (curved arrow), the protein could also be secreted by nearby cells. Note that the effect of OPN on reactive nitrogen intermediates (RNIs) and reactive oxygen intermediates (ROIs) is suppressive. Abbreviations: CSF, colony-stimulating factor; IFN, interferon; IL, interleukin; LPS, lipopolysaccharide; TNF, tumour necrosis factor.

In vivo

The expression of OPN in macrophages in vivo has been reported frequently in a variety of different models of tissue injury and pathology: macrophage expression of OPN is frequently associated with inflammation. This expression has, in many cases, been detected by both immunohistochemistry and in situ hybridisation, confirming that macrophages, which are generally identified by staining with marker antibodies, synthesise the protein. Table 1 summarises some of the many studies describing expression of OPN in macrophage cells in vivo in different pathologies. Although the list of pathologies where OPN is expressed in macrophages is long, a notable exception is the kidney, where OPN expression is upregulated in tubular and other epithelial cells following injury (including ischaemia, unilateral obstruction and diabetic nephropathy) but is typically not found in macrophages. In this tissue, expression of OPN in these tubular cells is correlated with macrophage influx; for example, in rats treated with deoxycorticosterone acetate, glomeruli that express higher levels of OPN had more infiltrating macrophages (Ref. Reference Hartner93).

Table 1. Osteopontin expression in macrophages in vivo

aCell types expressing osteopontin and/or the criteria used to determine that the expressing cells are macrophages.

bMethod of detection of osteopontin expression.

Abbreviations: BAL, bronchoalveolar fluid; LPS, lipopolysaccharide; CCL4, carbon tetrachloride; DOCA, deoxycorticosterone acetate; IF, immunofluorescence; IH, immunohistochemistry; iNOS, inducible nitric oxide; IP, intraperitoneal injection; ISH, in situ hybridisation; KO, knockout; OPN, osteopontin.

Regulation of macrophage function by OPN

Macrophage functions in the response to infection or injury can be divided into three broad areas: (1) production of cytokines or chemokines; (2) phagocytosis of bacteria or other particles, and killing of bacterial or other cells; and (3) antigen presentation. OPN has been implicated primarily in the first two of these functions. Studies on the role of OPN in macrophage function have been carried out using exogenously added protein, or the role of endogenous protein has been examined by the study of macrophages from OPN-deficient mice, or by using small interfering RNA (siRNA) or anti-OPN antibody. In some cases, unfortunately, the reported results are contradictory. To some extent, this is probably due to the heterogeneous nature of the macrophages themselves, where cells differentiated under various conditions might express different OPN receptors or have activated different signalling pathways. In addition, OPN itself is a heterogeneous protein found with different degrees of phosphorylation in different cell types (Ref. Reference Christensen10); the protein is also susceptible to proteolytic cleavage, and these cleavages can either activate (Ref. Reference Smith99) or inactivate (Ref. Reference Agnihotri29) the integrin-binding ability of the protein (Ref. Reference Yokosaki19) (Fig. 1). Thus, different proteolytic fragments could have different integrin-binding properties (Refs Reference Christensen28, Reference Agnihotri29). Whether and how OPN phosphorylation or glycosylation regulates its function outside of mineralised tissue is still an area of active investigation (Ref. Reference Kazanecki, Uzwiak and Denhardt100).

OPN receptors and expression on monocytes/macrophages

Monocytes and macrophages express a limited repertoire of integrins, but the expression of these molecules on macrophages in tissues is not well understood. Of the integrins known to bind OPN, cultured monocytes (such as THP-1, U937 and HL-60) express predominantly the α4β1 integrin (Ref. Reference Prieto, Eklund and Patarroyo101). HL-60 and THP-1 cells can adhere to OPN through the α4β1 integrin, but activation of the integrin with both Mn2+ and PMA is required for this effect (Ref. Reference Bayless15), suggesting that the affinity of this integrin for OPN is strictly regulated in monocytes. Primary monocytes isolated from human blood express low levels of α4, α5 and β1 integrins, and these are all upregulated as the cells differentiate to macrophages, as is the αxβ2 integrin (Ref. Reference Ammon102). In HL-60 cells, differentiation with PMA results in expression of the αvβ3 integrin as well as β1-containing integrins (Ref. Reference Atkins41). In mouse bone-marrow-derived monocytes, CSF1 (used to differentiate these cells into macrophages) stimulates expression of α4β1 and α5β1 (Ref. Reference Shima103). CSF1 also induces expression of the αvβ5 integrin, whereas CSF2 induces the αvβ3 integrin (Ref. Reference De Nichilo and Burns104). Myeloid-specific deletion of the αv integrin in mice results in immune defects, including development of colitis (Ref. Reference Lacy-Hulbert105), highlighting the importance of this integrin in macrophage function.

OPN effects on gene expression in macrophages

IL-12 and IL-10

OPN is widely thought to induce IL-12 expression in macrophages and to suppress the expression of IL-10, thereby regulating the T helper 1 (Th1)–Th2 bias of the adaptive immune system. Treatment of mouse resident peritoneal macrophages with purified OPN (from T cells or osteoblasts) induced secretion of IL-12 p70 directly, and suppressed expression of IL-10 induced in these cells by either LPS or IL-4 (Ref. Reference Ashkar106). These effects of OPN on macrophages were demonstrated to be due to OPN–αvβ3 and OPN–CD44 interactions, respectively. Subsequent work showed that OPN increased expression of both IL-12 and TNF in resident peritoneal macrophages, that OPN phosphorylation was required, and that this effect required only modest (175 ng/ml) OPN concentrations (Ref. Reference Weber25). Conversely, OPN produced in insect cells (and presumably post-translationally modified) had no effect on IL-12 p40 expression in resident macrophages. Similarly, there was no effect of bacterially produced OPN on IL-12 p40 secretion in murine bone marrow macrophages (Ref. Reference Potter107). However, when differentiated macrophages isolated from the lamina propria of colonic mucosa from healthy patients or from those with Crohn disease were treated with OPN (native, 25 µg/ml or 0.7 µm), IL-12 production was induced only in cells isolated from the diseased mucosa (Ref. Reference Sato89). This result suggests that the effect of OPN on IL-12 production in differentiated macrophages might require priming, perhaps involving regulation of integrin expression or affinity. The effect of OPN on IL-10 production has more support. A background-strain-specific increase in IL-10 induced by bacterial lipoprotein was reported in OPN−/− mice (Ref. Reference Potter107), and peritoneal macrophages from OPN-overexpressing transgenic mice produced significantly less IL-10 after LPS stimulation than did WT macrophages (Ref. Reference Isoda108): these results are consistent with an effect of endogenous OPN in suppressing IL-10 levels. However, OPN produced in insect cells did not suppress LPS-induced IL-10 production in peritoneal macrophages (Ref. Reference Abel109). The reason for these divergent results remains unclear: the phosphorylation state of OPN, the differentiation status of the macrophages and possible contaminants (discussed in more detail below) in the OPN preparations are possible explanations. Additional work using well-characterised OPN preparations and macrophage preparations with defined integrin expression could clarify this situation.

Several groups have examined the effect of OPN on IL-12 production in human monocytes from PBMCs. Very high concentrations of OPN (50 µg/ml or 1.4 µm) were required to increase IL-12 production in PBMCs (Ref. Reference Koguchi60). Similarly, native OPN at 25 µg/ml (0.9 µm) induced IL-12 in human PBMC monocytes to a similar level as that seen with LPS (Ref. Reference Sato89). In another study, OPN alone was unable to induce IL-12 in PBMCs (although the concentration used is unknown), but moderate OPN concentrations (1 µg/ml, 30 nm) could induce IL-12 in these cells when T cells were concurrently stimulated with CD3 (Ref. Reference O'Regan, Hayden and Berman110), through a mechanism dependent on CD40 ligand (CD40LG) and IFN-γ expression by stimulated T cells. PBMCs cocultured with P. marneffei expressed both OPN and IL-12: antibody to OPN inhibited IL-12 production in infected cells, and IL-12 production was observed only in the CD14+ monocyte population (Ref. Reference Koguchi60). Together, these results suggest that in some cases OPN alone might not be able to induce IL-12 expression directly, but might cooperate with other signalling molecules, perhaps through receptor or signalling pathway crosstalk. The use of micromolar concentrations of OPN raises some concerns, because low-level contamination (less than 0.1%) of such preparations with cytokines that function at nano- or picomolar concentrations (Ref. Reference Zhang and Wang111) could be responsible for the reported effects.

Contaminating LPS might be an additional confounding factor in these studies. Polymyxin-B affinity chromatography (which removes LPS) removed the IL-12-inducing activity on human blood monocytes from several commercially available preparations of OPN, suggesting that some of the cytokine-inducing effects of OPN resulted from endotoxin contamination (Ref. Reference Konno112). Again, because OPN is often used at moderately high concentrations (1–10 µg/ml), even endotoxin levels less than 1 EU/μg could affect the results. A more extended use of polymyxin-B-treated preparations of OPN is required to prove that OPN itself regulates cytokine production in monocytes.

Other cytokines

OPN increased the expression of TNF, but not of IL-6 or IL-1β, in resident mouse peritoneal macrophages (Ref. Reference Weber25). However, in LPS-treated peritoneal macrophages, OPN treatment increased the expression of all these cytokines over that seen with LPS alone, and anti-OPN reduced the expression of both IL-1β and TNF (Ref. Reference Aziz113). After treatment with zymosan (a yeast cell wall preparation also known as β-glucan), peritoneal macrophages from OPN−/− mice expressed significantly less IL-10 and IL-1β than WT cells; expression of intracellular OPN potentiated induction of these cytokines by zymosan through a mechanism involving ERK (MAPK1; mitogen-activated protein kinase 1) phosphorylation (Ref. Reference Inoue34). Stimulation of murine bone marrow macrophages with titanium particles resulted in lower secretion of several cytokines, including TNF, IL-1α, IL-1β, IL-6, CSF1 and CCL3 [chemokine (C–C) motif ligand 3], from OPN−/− cells as compared with similarly treated WT cells (Ref. Reference Shimizu114), implicating OPN in the regulation of expression of these cytokines/chemokines. In human monocytes isolated from PBMCs, OPN (100 nm/3.75 µg/ml) induced expression of IL-1β, TNF, IL-8 and IL-6, whereas expression of IL-10 was reduced (Ref. Reference Naldini115). The induction of IL-1β was dose dependent, was seen at both the protein and mRNA levels, and did not require the RGD sequence of OPN. These effects of OPN on gene expression paralleled increased phosphorylation of p38 MAPK (Ref. Reference Naldini115).

Alternative alleles encoding OPN have been identified in different strains of mice; these alleles correlate with strain-specific susceptibility to Rickettsia infection, with susceptible mice such as C3H expressing allele B, and several resistant strains expressing allele A (Ref. Reference Patarca, Saavedra and Cantor116). The proteins encoded by these two alleles differ in nine amino acids, some of which are close to integrin-binding sites (Ref. Reference Ono, Yamamoto and Nose117). Synthetic OPN translated in vitro from these different alleles significantly upregulated TNF, IL-1β and IFN-γ mRNA levels in mouse bone marrow macrophages. However, there was a substantial difference in the potency of the two alleles, with allele B having a much smaller effect than allele A (Ref. Reference Miyazaki118). Owing to the unusual in vitro translation method used to produce OPN, the protein concentration and post-translational modifications required for these effects are unknown.

OPN effects on other genes in macrophages

OPN has been implicated in the regulation of chemokine expression. Incubation of human PBMCs with synovial fluid from rheumatoid arthritic joints, which contains abundant OPN, increased the expression of chemokine CSF1 and CCL4; this effect was partially blocked by antibodies to OPN (Ref. Reference Zheng12). The expression of these two chemokines was seen in CD14+ monocytes but not in the CD14 population, and the results could be mimicked with purified OPN at 1 µg/ml (30 nm) or less. Peptide mapping showed that this activity of OPN was not associated with the RGD or SVVYGLR sequences, but was rather found in the sequence from amino acids 50 to 83, which is immediately adjacent to a sequence that was previously implicated in OPN binding to lymphocytes (Ref. Reference Cao11). The receptor for this sequence is still undefined, because anti-CD44 did not block the effects of OPN in this system.

OPN (10 nm) treatment of RAW264.7 cells results in decreased expression of the mitochondrial protein cytochrome c oxidase through a CD44-dependent and αvβ3-independent mechanism (Ref. Reference Gao119). OPN (5–10 nm) also increases expression of CD44 by increasing its half-life in a GRGDS-dependent mechanism in both RAW264.7 and ANA-1 cells, but there is no effect on the levels of CD44 mRNA (Ref. Reference Marroquin120). Accordingly, OPN increases adhesion of these cell types to the CD44 ligand hyaluronic acid. OPN was also shown to increase TIMP1 (TIMP metalloproteinase inhibitor 1) expression in PBMCs, an effect seen only in the CD14+ population (Ref. Reference Vaschetto121). In HL-60 cells, soluble OPN increases the expression of CA2 (carbonic anhydrase II) (Ref. Reference Steitz122).

Taken together, these results strongly suggest that OPN can regulate the expression of many gene products, including inflammatory cytokines, in cells of the monocyte/macrophage lineage. However, the high concentrations of protein required and the potential role of LPS or other contaminants in these effects must be taken into account, and future studies should directly address these issues.

OPN in macrophage effector functions

Effector functions of macrophages include the ability of these cells to engulf and destroy bacteria, mammalian cells and particles through phagocytosis and to kill bacteria and foreign invaders through production of cytotoxic compounds such as NO and reactive oxygen species (ROS). Mobility of these cells is important in their ability to carry out these functions. In this section, the role of OPN in these functions is summarised.

OPN and iNOS expression in macrophages

The role of OPN in the production of NO and in the expression of inducible nitric oxide synthase (iNOS/NOS2) in macrophages has been extensively studied. In vitro, OPN suppresses NO production and NOS2 mRNA levels in IFN-γ- and LPS-treated RAW264.7 mouse macrophages, although these effects are seen only within a very narrow dose range and in specific physiological contexts (Refs Reference Rollo, Laskin and Denhardt123, Reference Tian124). Endogenous OPN also suppresses NO production in a feedback loop, because GRGDS peptide, which presumably blocks OPN binding to integrins such as αvβ3, increases NO production in LPS-treated macrophages (Ref. Reference Guo54). OPN-specific siRNA but not a mismatched sequence increased the expression of NOS2 through a mechanism that involved the NOS2 promoter (Ref. Reference Gao125). Exogenous OPN (50 µm or 1.7 mg/ml) could overcome the effects of siRNA and suppress NOS2 transcription. Chromatin immunoprecipitation (ChIP) experiments demonstrated that blocking OPN expression increased the binding of STAT1 (signal transducer and activator of transcription 1) to the NOS2 promoter; the mechanism involves the ability of OPN to decrease STAT1 stability, which in turn results from increased STAT1 ubiquitination (Ref. Reference Gao125). These results obtained in RAW264.7 cells were confirmed in primary murine bone marrow macrophages (Ref. Reference Gao125).

In vivo, the effect of OPN on NO production is not as well defined as in the RAW264.7 cell line. A mouse model of in vivo LPS exposure – caecal ligation and puncture – was used to assess the role of OPN in NOS2 expression in vivo. In these experiments, OPN deficiency resulted in increased expression of NOS2 and phosphorylated STAT1 and reduced STAT1 ubiquitination in bone marrow macrophages or liver tissue 24 h after treatment, consistent with the in vitro results (Ref. Reference Guo126). Other results from OPN-deficient mice, however, suggest the opposite effect. For instance, reduced production of NO was reported in elicited peritoneal macrophages from OPN-deficient mice as compared with WT after LPS and IFN-γ treatment (Ref. Reference Bourassa, Monaghan and Rittling127). In dextran sodium sulfate (DSS)-induced colitits, lower NOS2 levels were observed in the inflamed intestinal tissues of OPN-deficient mice as compared with WT (Ref. Reference Heilmann128). These lower levels of NOS2 and NO in OPN-deficient animals are inconsistent with the idea that OPN suppresses NOS2 expression, and suggest that the effect of OPN on NOS2 expression might be context specific.

OPN and cell killing

In cytotoxicity assays, OPN-deficient peritoneal macrophages stimulated with IFN-γ and LPS had an impaired ability to kill tumour cells, an effect that correlated with reduced production of NO (Ref. Reference Bourassa, Monaghan and Rittling127). Resident peritoneal macrophages were not affected by OPN deficiency, providing further evidence that the state of differentiation or activation of macrophages regulates their response to OPN. Macrophages differentiated in vitro with CSF1 are resistant to M. tuberculosis infection as compared to those differentiated with CSF2 (Ref. Reference Khajoee61), and OPN is one of the most highly upregulated genes correlating with resistance. Accordingly, exogenous OPN was able to inhibit the proliferation of M. tuberculosis in infected sensitive macrophages, and significantly increased superoxide production (Ref. Reference Khajoee61). These results are consistent with experiments showing that BCG replication was more extensive in OPN-deficient peritoneal macrophages than in corresponding WT cells (Ref. Reference Nau129), although no differences in NO production were noted and superoxide production was not assessed. Together, these results support a role for OPN in enhancing macrophage cytotoxicity, although further work is needed to understand the mechanism of these effects.

OPN and phagocytosis

OPN-deficient lamina propria macrophages from mice with DSS-induced colitis were impaired in the phagocytosis of fluorescein isothiocyanate (FITC)-labelled Escherichia coli as compared with macrophages from WT mice (Ref. Reference Heilmann128). Bone marrow macrophages from OPN−/− mice also showed impaired phagocytosis of fluorescent beads, and reduced nuclear factor (NF)-κB activation following phagocytosis (Ref. Reference Shimizu114). Furthermore, phagocytosis in human macrophages was induced by 100 ng/ml OPN, but not by 500 ng/ml (Ref. Reference Heilmann128). Thioglycollate-elicited mouse peritoneal macrophages from WT and OPN-deficient mice, however, had equal abilities to phagocytose FITC-labelled Listeria monocytogenes (Ref. Reference Bourassa, Monaghan and Rittling127).

Phagocytosis of the fungal opportunistic pathogen Pneumocystis by macrophages leads to clearance of these organisms. In the absence of an adaptive immune response (on a RAG2−/− background), OPN-deficient mice are susceptible to these organisms, unlike WT mice. Phagocytosis of these organisms was severely compromised in macrophages from OPN−/− mice, through a mechanism involving colocalisation of intracellular OPN with the pattern-recognition receptors TLR2, dectin and mannose receptor (Ref. Reference Inoue34). The reduced phagocytosis in the absence of OPN was accompanied by reduced killing of the phagocytosed organisms resulting from defective production of ROS.

It has also been suggested that OPN can function as an opsonin to facilitate phagocytosis. Microspheres with different chemistries were all internalised by J477A.1 macrophages more efficiently when coated with OPN than when uncoated, but in some cases the effect was similar to that seen with immunoglobulin G (IgG) coating (Ref. Reference Pedraza130). OPN also binds two bacterial species – Streptococcus agalactiae and Staphylococcus aureus – in a Ca2+-dependent manner, with maximal binding at 10 µg/ml OPN (Ref. Reference Schack21). OPN-coated bacteria were somewhat more efficiently phagocytosed by PMA-stimulated U937 cells, whereas OPN-coated latex beads were substantially more efficiently phagocytosed (Ref. Reference Schack21) in an αxβ2-dependent mechanism.

Together, these results implicate OPN in the regulation of macrophage effector functions, including cell killing and phagocytosis, but suggest that the differentiation state or cellular milieu of the macrophage preparations might determine the effect of OPN. Differential expression or regulated affinity of OPN-binding integrins might underlie some of these differences. An important future direction to understand these differences is to directly compare the role of OPN in macrophage effector functions using macrophage preparations isolated from different tissues or at different stages of differentiation.

OPN and macrophage migration

Integrins are intimately involved in the regulation of cellular migration, and OPN as a small integrin-binding protein can influence this process in macrophage cells. This has been well demonstrated both in vivo and in vitro. In the following sections, exogenous OPN refers to injected or added protein, whereas endogenous OPN refers to the protein present in the whole animal or made by macrophages. The role of endogenous protein has been mostly tested by analysis of OPN-deficient mice or cells.

In vivo: exogenous OPN

Injection of purified OPN into the skin of mice (Ref. Reference Singh131) or rats (Ref. Reference Giachelli132) resulted in macrophage accumulation at the injection site; a neutralising anti-OPN antibody decreased macrophage accumulation at sites of injection of the chemoattractant fMLP (Ref. Reference Giachelli132). Similarly, in an air pouch assay, injection of OPN (either thrombin-cleaved or intact) resulted in macrophage accumulation in the air pouch exudate (Ref. Reference Marcondes133), which was inhibited by anti-CD44 (Ref. Reference Marcondes133). OPN injection into the peritoneum of mice resulted in a five- to sixfold increase in total cells, 90% of which were Mac1+ (ITGAM+) (Ref. Reference Weber25). In the vitreous space of the eyes of normal mice OPN (both intact and N- and C-terminal fragments) recruited F4/80+ (EMR1+) cells (Ref. Reference Hikita84).

In vivo: endogenous OPN

The role of endogenous OPN in macrophage recruitment into the peritoneum or other sites has been tested using OPN-deficient mice, but there remains a lack of consensus on the effect. Macrophages are recruited into the peritoneum after intraperitoneal thioglycollate injection. The number of total cells recruited has been reported to be either fewer (Ref. Reference Bruemmer134) or greater (Ref. Reference Nau129) in OPN-deficient mice as compared with WT. In subcutaneous air pouches there was no difference in the number of macrophages that accumulated after OPN injection between the two genotypes (Ref. Reference Marcondes133); however, the macrophages that accumulated in OPN-deficient air pouches in response to OPN injection expressed higher levels of α4 integrin than those from WT mice, suggesting that there are alterations in the population of elicited macrophage cells in OPN-deficient mice. If OPN promotes macrophage migration, one would predict that the number of elicited macrophages would be lower in the OPN-deficient mice. Thus, the mechanism of the observed increased macrophage accumulation in OPN−/− mice remains unclear.

In vitro: effect of exogenous OPN

OPN induces migration of the MH-s mouse alveolar macrophage cell line, which expresses both β3 integrin and CD44 (Ref. Reference Weber25). In chemotaxis and chemokinesis assays, OPN and its C-terminal fragment increased migration, and this effect was blocked by anti-CD44 antibody; the N-terminal fragment was ineffective in this assay. By contrast, haptotaxis, or migration on an OPN-coated surface, was induced by both N-terminal and C-terminal OPN fragments, and phosphorylation of the N-terminal fragment was required for this activity, which was blocked by RGD peptides, suggesting αvβ3 interactions. Similarly, phosphorylation of the N-terminal fragment of OPN was required for MH-s cell spreading on OPN (Ref. Reference Weber25). Human monocytes, when activated with IL-1, migrate towards bovine milk OPN as efficiently as to normal human serum (Ref. Reference Schack21).

In vitro: effect of endogenous OPN

The role of OPN produced by macrophages themselves has been tested by examining the migratory abilities of OPN-deficient macrophages. Elicited peritoneal macrophages from OPN-deficient mice showed reduced migration (as compared with WT cells) in vitro towards mouse serum (Ref. Reference Duvall135), fMLP (Ref. Reference Zhu32) or CCL2 (Refs Reference Zhu32, Reference Nomiyama67, Reference Bruemmer134, Reference Duvall135), but not to CSF1 or high concentrations (6.5 nm) of OPN (Ref. Reference Zhu32). Deficient migration was partially (Ref. Reference Nomiyama67) or fully (Ref. Reference Zhu32) restored by OPN coated on the surface, whereas only the highest concentration of soluble OPN tested (5 µg/ml or 140 nm) could restore migration of OPN−/− macrophages towards the chemoattractant fMLP to WT levels (Ref. Reference Zhu32). The N-terminal half of OPN is required for this effect, but cleavage by thrombin is not required (Ref. Reference Zhu32). An intracellular form of OPN in peritoneal macrophages identified by immunofluorescence and seen only in permeabilised cells colocalises with CD44 at the leading edge of migrating cells. OPN deficiency results in reduced cell-surface expression of CD44, which is required for macrophage migration (Ref. Reference Zhu32).

OPN in macrophage differentiation

An siRNA approach was used to assess the role of OPN in RAW264.7 macrophage cells (Ref. Reference Nystrom, Duner and Hultgardh-Nilsson136). OPN expression was downregulated by 90% in two stably transfected clones expressing OPN short hairpin RNA. OPN-downregulated cells were less adherent, and had reduced expression of CD44. Nonstimulated migration was reduced, and the OPN-downregulated cells were more susceptible to apoptosis in serum-free medium. The expression of the macrophage differentiation marker MSR1 (macrophage scavenger receptor 1) was downregulated, as was expression of IL-12, but the expression of IL-10 and of TNF was unaffected. Interestingly, exogenously added OPN could not compensate for the lack of OPN expression. The authors of this report suggest that together these effects support a role for endogenous, likely intracellular, OPN in macrophage differentiation.

Alterations in macrophage numbers in OPN-deficient mice

Because there is considerable evidence that OPN regulates macrophage migration, this effect should be manifest by a reduction of macrophage numbers in tissues of OPN-deficient mice in response to pathology. Indeed, this has been reported in several instances.

In renal disease

OPN is strongly implicated in renal disease, where its upregulation in tubular epithelial cells is thought to contribute to macrophage infiltration into renal tissues. This has been demonstrated in several different models of renal injury in rodents (Table 2). Together, these results are consistent in implicating OPN in supporting macrophage accumulation in various forms of renal injury, and in contributing to the pathological responses to these injuries.

Table 2. Effect of osteopontin on macrophage accumulation in renal injury

Abbreviations: OPN, osteopontin; UUL, unilateral ureteral ligation.

In granulomas and autoimmunity

Granulomas are organised collections of macrophages formed in response to bacteria or particles that cannot be effectively removed. Intravenous injection of zymosan results in granuloma formation in the liver. In this model, OPN deficiency resulted in a reduced number of granulomas, accompanied by a reduction in the total number of macrophages. Transgenic mice overexpressing OPN in lymphoid cells responded to zymosan injection with increased granuloma numbers accompanied by increased levels of NOS2 mRNA. These results suggest that OPN regulates inflammatory cell, including macrophage, infiltration into the liver, especially at later stages of this disease (Ref. Reference Morimoto144). Pulmonary granulomas induced in mice with Schistosoma mansoni eggs were also dependent on OPN: the accumulation of granulomas was delayed in OPN-deficient mice and these granulomas contained significantly fewer macrophages (Ref. Reference O'Regan145). In experimentally induced autoimmune uveitis, an autoimmune disease of the eye, there was a reduction in the number of granulomas in OPN-deficient mice, in parallel with a decreased number of inflammatory infiltrating cells, including F4/80+ macrophages (Ref. Reference Hikita84). Granulomas arising after infection with BCG, however, were larger in OPN−/− mice and were accompanied by increased bacterial load, reflecting impaired bacterial clearance in the absence of OPN (Ref. Reference Nau129). Accordingly, in vitro, BCG grew more rapidly in macrophages from OPN−/− mice. Together, these results are consistent with a role for OPN in supporting macrophage accumulation in granulomas. The paradoxical appearance of larger granulomas in BCG infection might in fact be a consequence of reduced macrophage accumulation at early times of disease: the consequent attenuation of bacterial killing can lead ultimately to larger granulomas at later times as the host attempts to control the bacterial infection.

In tumours

OPN-producing tumours in WT mice contained more macrophages than OPN-deficient tumours, and more of the macrophages in OPN-producing tumours were positive for the mannose receptor (Ref. Reference Crawford, Matrisian and Liaw146). However, in a model of spontaneous tumour development, where both the tumours and the hosts are OPN deficient, macrophage accumulation was independent of OPN status (Ref. Reference Feng and Rittling147). Migration of tumour cells with silenced OPN expression was reduced, but could be restored by coculture with human macrophages or macrophage-derived conditioned medium: OPN was shown by blocking antibodies and siRNA techniques to be required for the effects on tumour cell migration (Ref. Reference Cheng148). These results suggest that OPN expression in stromal macrophages might regulate tumour cell function.

In obesity

OPN-deficient mice maintained on a high-fat diet gained weight similarly to WT animals. However, OPN-deficient mice had improved insulin sensitivity, similar to that of nonobese mice, in stark contrast to results in WT mice (Ref. Reference Nomiyama67). This increased insulin sensitivity was associated with reduced macrophage accumulation in adipose tissue, together with reduced expression of IL-6, TNF, NOS2 and CCL2. Furthermore, plasma levels of inflammatory markers (IL-6, CCL2 and SERPINE1) but not adipokines (adiponectin, leptin and resistin) were reduced in obese OPN-deficient mice. Consistent with these results, neutralising antibody to OPN reduced macrophage numbers in liver and adipose tissue in obese mice, accompanied by increased insulin sensitivity and an increased proportion of apoptotic macrophages (Ref. Reference Kiefer149). Although these results suggest that OPN protects macrophages from apoptosis, the same effect could be due to decreased macrophage infiltration if the total number of apoptotic macrophages is not altered. In genetically obese ob/ob mice treated with d-galactosamine to induce liver injury, neutralising antibody to OPN reduced liver injury, in parallel with reduced macrophage infiltration (Ref. Reference Kwon150).

In colitis

The role of OPN in DSS-induced colitis has been explored in a series of studies (Refs Reference Heilmann128, Reference da Silva151, Reference da Silva152, Reference Zhong153). Two groups reported an increased inflammatory response to DSS in OPN-deficient mice (Refs Reference Heilmann128, Reference da Silva152). Increased accumulation of neutrophils and total apoptotic cells in the colons of OPN-deficient mice in one study was suggested to be due to reduced clearance of apoptotic neutrophils by OPN-deficient macrophages (Ref. Reference da Silva152). In another study, although there was no difference in macrophage accumulation in WT or OPN-deficient diseased colons, NOS2 expression was strongly reduced in DSS-treated OPN−/− mice, further supporting the idea that impaired macrophage function in the absence of OPN increases pathology (Ref. Reference Heilmann128). Conflicting results, however, were obtained in a third study of DSS-induced colitis, where pathology was suppressed in the absence of OPN (Ref. Reference Zhong153): in this case, reduced macrophage infiltration in the inflamed colonic tissue in OPN−/− mice was suggested to be responsible for the suppressed pathological response. Different background strains [C57BL/6 (Refs Reference Heilmann128, Reference da Silva152) versus Black Swiss (Ref. Reference Zhong153)] were used in these studies, which might underlie the divergent results. Whether OPN regulates macrophage accumulation or function in DSS-induced colitis will require further studies using matched mice (preferably littermates) of well-defined genetic background.

Conclusions and therapeutic implications

There are two important conclusions to be drawn from studies of the role of OPN in macrophage function. First, it is clear that the protein is important in the migration of these cells, as shown by extensive in vitro and in vivo studies. Second, its role in other macrophage functions such as phagocytosis and bacterial/cell killing is also supported by experimental results, but more work is required to clarify the effects and the mechanism of action of OPN. Particularly compelling are experiments using OPN-deficient mice or cells, because these studies are not as susceptible to experimental variabilities as are those using purified preparations of OPN. These experimental variabilities raise concerns about the role of OPN described in experiments in vitro. For instance, the role of OPN in cytokine production in macrophages/monocytes remains controversial, and experiments with rigorously defined sources of OPN are required to resolve these conflicts. In particular, OPN preparations must be shown to be free of LPS, and the use of preparations of OPN where contaminating proteins have been inactivated (Ref. Reference Jain26) is also required.

Because OPN has the potential to regulate numerous aspects of macrophage functions, various therapeutic opportunities exist to exploit these effects. However, the effect of OPN might be either helpful (in the case of infection, where macrophage function is beneficial for the innate immune response) or detrimental (in the case of injury or autoimmune disease, where macrophage function can cause tissue damage). Thus, it will be important to have a full understanding of the roles of OPN in macrophage function to take advantage of these effects therapeutically. An overarching observation apparent from the data reviewed here is the variable results that have been obtained by different investigators in defining the precise role of OPN in macrophage function. Although some of this variability might be due to artefacts, some might also be due to heterogeneity in macrophages, in terms of their expression of OPN receptors under different conditions of stimulation or differentiation, as well as heterogeneity in OPN forms used in vitro and present in vivo in terms of their post-translational modifications and proteolytic cleavage forms. These heterogeneities in OPN forms, while presenting some experimental difficulties, might also provide an important therapeutic advantage. If indeed specific forms of OPN have unique abilities to regulate macrophage function under specific circumstances, then reagents targeting these forms, as either agonists or antagonists, might be able to affect specific functions of macrophages while leaving others unaffected. The therapeutic opportunities in this area are many, and understanding these heterogeneities will be key to exploiting these opportunities.

Acknowledgements and funding

The author thanks the reviewers for their helpful comments.

References

References

1Senger, D.R. et al. (1989) Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin. Biochimica Biophysica Acta 966, 43-48CrossRefGoogle Scholar
2Oldberg, A., Franzen, A. and Heinegard, D. (1986) Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proceedings of the National Academy of Sciences of the United States of America 83, 8819-8823Google Scholar
3Brown, L.F. et al. (1992) Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Molecular Biology of the Cell 3, 1169-1180Google Scholar
4Rittling, S.R. et al. (2003) Osteopontin, a surprisingly flexible cytokine: functions revealed from knockout mice. In Contemporary Immunology: Cytokine Knockouts (2nd edn) (Fantuzzi, G., ed.), pp. 379-393, Humana Press Inc., Totowa, NJCrossRefGoogle Scholar
5Weber, G.F. and Cantor, H. (1996) The immunology of Eta-1/osteopontin. Cytokine and Growth Factor Reviews 7, 241-248CrossRefGoogle ScholarPubMed
6Rittling, S.R. and Chambers, A.F. (2004) Role of osteopontin in tumour progression. British Journal of Cancer 90, 1877-1881CrossRefGoogle ScholarPubMed
7Ramaiah, S.K. and Rittling, S. (2007) Role of osteopontin in regulating hepatic inflammatory responses and toxic liver injury. Expert Opinion on Drug Metabolism and Toxicology 3, 519-526CrossRefGoogle ScholarPubMed
8Giachelli, C. (2005) Inducers and inhibitors of biomineralization: lessons from pathological calcification. Orthodontics and Craniofacial Research 8, 229-231CrossRefGoogle ScholarPubMed
9Scatena, M., Liaw, L. and Giachelli, C.M. (2007) Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology 27, 2302-2309Google Scholar
10Christensen, B. et al. (2007) Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties. Journal of Biological Chemistry 282, 19463-19472CrossRefGoogle ScholarPubMed
11Cao, Z. et al. (2008) A novel functional motif of osteopontin for human lymphocyte migration and survival. Molecular Immunology 45, 3683-3692Google Scholar
12Zheng, W. et al. (2009) Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1beta through the NF-kappaB and MAPK pathways in rheumatoid arthritis. Arthritis and Rheumatism 60, 1957-1965CrossRefGoogle ScholarPubMed
13Hu, D.D. et al. (1995) A biochemical characterization of the binding of osteopontin to integrins αvβ1 and αvβ5. Journal of Biological Chemistry 270, 26232-26238Google Scholar
14Hu, D.D., Hoyer, J.R. and Smith, J.W. (1995) Calcium suppresses cell adhesion to osteopontin by attenuating binding affinity for integrin αvβ3. Journal of Biological Chemistry 270, 9917-9925CrossRefGoogle Scholar
15Bayless, K.J. et al. (1998) Osteopontin is a ligand for the α4β1 integrin. Journal of Cell Science 111, 1165-1174CrossRefGoogle ScholarPubMed
16Barry, S.T. et al. (2000) Analysis of the alpha4beta1 integrin–osteopontin interaction. Experimental Cell Research 258, 342-351Google Scholar
17Yokosaki, Y. et al. (1999) The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. Journal of Biological Chemistry 274, 36328-36334CrossRefGoogle Scholar
18Barry, S.T. et al. (2000) A regulated interaction between alpha5beta1 integrin and osteopontin. Biochemical and Biophysical Research Communications 267, 764-769CrossRefGoogle ScholarPubMed
19Yokosaki, Y. et al. (2005) Distinct structural requirements for binding of the integrins alphavbeta6, alphavbeta3, alphavbeta5, alpha5beta1 and alpha9beta1 to osteopontin. Matrix Biology 24, 418-427Google Scholar
20Denda, S., Reichardt, L.F. and Müller, U. (1998) Identification of osteopontin as a novel ligand for the integrin α8β1 and potential roles for this integrin–ligand interaction in kidney morphogenesis. Molecular Biology of the Cell 9, 1425-1435CrossRefGoogle ScholarPubMed
21Schack, L. et al. (2009) Osteopontin enhances phagocytosis through a novel osteopontin receptor, the {alpha}X{beta}2 integrin. Journal of Immunology 182, 6943-6950CrossRefGoogle Scholar
22Weber, G.F. et al. (1996) Receptor-ligand interaction between CD44 and osteopontin (ETA-1). Science 271, 509-512CrossRefGoogle Scholar
23Smith, L.L. et al. (1999) CD44 is not an adhesive receptor for osteopontin. Journal of Cellular Biochemistry 73, 20-303.0.CO;2-3>CrossRefGoogle Scholar
24Katagiri, Y.U. et al. (1999) CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine–glycine–aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Research 59, 219-226Google Scholar
25Weber, G.F. et al. (2002) Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation. Journal of Leukocyte Biology 72, 752-761Google Scholar
26Jain, A. et al. (2002) Three SIBLINGs (SmallIntegrin-Binding LIgand, N-linked Glycoproteins) enhance factor H's cofactor activity enabling MCP-like cellular evasion of complement-mediated attack. Journal of Biological Chemistry 277, 13700-13708Google Scholar
27Rittling, S.R. et al. (2002) Tumor-derived osteopontin is soluble, not matrix associated. Journal of Biological Chemistry 277, 9175-9182CrossRefGoogle Scholar
28Christensen, B. et al. (2010) Osteopontin is cleaved at multiple sites close to its integrin-binding motifs in milk and is a novel substrate for plasmin and cathepsin D. Journal of Biological Chemistry 285, 7929-7937Google Scholar
29Agnihotri, R. et al. (2001) Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). Journal of Biological Chemistry 276, 28261-28267Google Scholar
30Sharif, S.A. et al. (2009) Thrombin-activatable carboxypeptidase B cleavage of osteopontin regulates neutrophil survival and synoviocyte binding in rheumatoid arthritis. Arthritis and Rheumatism 60, 2902-2912Google Scholar
31Zohar, R. et al. (2000) Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. Journal of Cellular Physiology 184, 118-1303.0.CO;2-Y>CrossRefGoogle ScholarPubMed
32Zhu, B. et al. (2004) Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin. Journal of Cellular Physiology 198, 155-167Google Scholar
33Cantor, H. and Shinohara, M.L. (2009) Regulation of T-helper-cell lineage development by osteopontin: the inside story. Nature Reviews. Immunology 9, 137-141CrossRefGoogle ScholarPubMed
34Inoue, M. et al. (2010) Cutting edge: critical role of intracellular osteopontin in antifungal innate immune responses. Journal of Immunology 186, 19-23Google Scholar
35Rittling, S.R. et al. (1998) Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. Journal of Bone amd Mineral Research 13, 1101-1111CrossRefGoogle ScholarPubMed
36Liaw, L. et al. (1998) Altered wound healing in mice lacking a functional osteopontin gene (spp1). Journal of Clinical Investigation 101, 1468-1478CrossRefGoogle ScholarPubMed
37Lund, S., Giachelli, C. and Scatena, M. (2009) The role of osteopontin in inflammatory processes. Journal of Cell Communication and Signaling 3, 311-322CrossRefGoogle ScholarPubMed
38Wang, K.X. and Denhardt, D.T. (2008) Osteopontin: role in immune regulation and stress responses. Cytokine and Growth Factor Reviews 19, 333-345Google Scholar
39Buback, F. et al. (2009) Osteopontin and the skin: multiple emerging roles in cutaneous biology and pathology. Experimental Dermatology 18, 750-759CrossRefGoogle Scholar
40Bellahcene, A. et al. (2008) Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nature Reviews. Cancer 8, 212-226CrossRefGoogle ScholarPubMed
41Atkins, K. et al. (1998) Coordinate expression of OPN and associated receptors during monocyte/macrophage differentiation of HL-60 cells. Journal of Cellular Physiology 175, 229-2373.0.CO;2-3>CrossRefGoogle ScholarPubMed
42Oyama, Y. et al. (2002) PPARgamma ligand inhibits osteopontin gene expression through interference with binding of nuclear factors to A/T-rich sequence in THP-1 cells. Circulation Research 90, 348-355Google Scholar
43Suzuki, H. et al. (2009) The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. Nature Genetics 41, 553-562Google Scholar
44Atkins, K.B., Simpson, R.U. and Somerman, M.J. (1997) Stimulation of osteopontin mRNA expression in HL-60 cells is independent of differentiation. Archives of Biochemistry and Biophysics 343, 157-163CrossRefGoogle ScholarPubMed
45Nakamachi, T. et al. (2007) PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes. Diabetes 56, 1662-1670CrossRefGoogle ScholarPubMed
46Li, X., O'Regan, A.W. and Berman, J.S. (2003) IFN-gamma induction of osteopontin expression in human monocytoid cells. Journal of Interferon and Cytokine Research 23, 259-265CrossRefGoogle ScholarPubMed
47Miyazaki, Y. et al. (1995) Expression of osteopontin in a macrophage cell line and in transgenic mice with pulmonary fibrosis resulting from the lung expression of a tumor necrosis factor-alpha transgene. Annals of the New York Academy of Sciences 760, 334-341CrossRefGoogle Scholar
48Wuthrich, R.P. et al. (1998) Enhanced osteopontin expression and macrophage infiltration in MRL-Fas(lpr) mice with lupus nephritis. Autoimmunity 28, 139-150CrossRefGoogle ScholarPubMed
49Konno, S. et al. (2006) Interleukin-10 and Th2 cytokines differentially regulate osteopontin expression in human monocytes and dendritic cells. Journal of Interferon and Cytokine Research 26, 562-567CrossRefGoogle ScholarPubMed
50Samuvel, D.J. et al. (2010) Adipocyte-mononuclear cell interaction, Toll-like receptor 4 activation, and high glucose synergistically up-regulate osteopontin expression via an interleukin 6-mediated mechanism. Journal of Biological Chemistry 285, 3916-3927CrossRefGoogle ScholarPubMed
51Rollo, E.E. and Denhardt, D.T. (1996) Differential effects of osteopontin on the cytotoxic activity of macrophages from young and old mice. Immunology 88, 642-647CrossRefGoogle ScholarPubMed
52Solinas, G. et al. (2010) Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for m2-polarization, influencing tumor cell motility. Journal of Immunology 185, 642-652CrossRefGoogle ScholarPubMed
53Ogawa, D. et al. (2005) Liver X receptor agonists inhibit cytokine-induced osteopontin expression in macrophages through interference with activator protein-1 signaling pathways. Circulation Research 96, e59-e67Google Scholar
54Guo, H. et al. (2001) Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macrophages. Journal of Immunology 166, 1079-1086CrossRefGoogle ScholarPubMed
55Gao, C. et al. (2004) S-nitrosylation of heterogeneous nuclear ribonucleoprotein A/B regulates osteopontin transcription in endotoxin-stimulated murine macrophages. Journal of Biological Chemistry 279, 11236-11243Google Scholar
56Takahashi, F. et al. (2000) Osteopontin is induced by nitric oxide in RAW 264.7 cells. IUBMB Life 49, 217-221CrossRefGoogle ScholarPubMed
57Gao, C. et al. (2005) Transcriptional regulatory functions of heterogeneous nuclear ribonucleoprotein-U and -A/B in endotoxin-mediated macrophage expression of osteopontin. Journal of Immunology 175, 523-530CrossRefGoogle Scholar
58Zhao, W. et al. (2010) Differential expression of intracellular and secreted osteopontin isoforms by murine macrophages in response to toll-like receptor agonists. Journal of Biological Chemistry 285, 20452-20461Google Scholar
59Nares, S. et al. (2009) Rapid myeloid cell transcriptional and proteomic responses to periodontopathogenic porphyromonas gingivalis. American Journal of Pathology 174, 1400-1414CrossRefGoogle ScholarPubMed
60Koguchi, Y. et al. (2002) Penicillium marneffei causes osteopontin-mediated production of interleukin-12 by peripheral blood mononuclear cells. Infection and Immunity 70, 1042-1048Google Scholar
61Khajoee, V. et al. (2006) Novel roles of osteopontin and CXC chemokine ligand 7 in the defence against mycobacterial infection. Clinical and Experimental Immunology 143, 260-268Google Scholar
62Wang, Y. et al. (2000) Increased expression of osteopontin in activated Kupffer cells and hepatic macrophages during macrophage migration in Propionibacterium acnes-treated rat liver. Journal of Gastroenterology 35, 696-701Google Scholar
63Ragno, S. et al. (2001) Changes in gene expression in macrophages infected with Mycobacterium tuberculosis: a combined transcriptomic and proteomic approach. Immunology 104, 99-108CrossRefGoogle ScholarPubMed
64van der Windt, G.J. et al. (2009) Osteopontin is not crucial to protective immunity during murine tuberculosis. Immunology 128, e766-e776CrossRefGoogle Scholar
65Kohan, M. et al. (2007) Enhanced osteopontin expression in a murine model of allergen-induced airway remodelling. Clinical and Experimental Allergy 37, 1444-1454Google Scholar
66Prasse, A. et al. (2009) Essential role of osteopontin in smoking-related interstitial lung diseases. American Journal of Pathology 174, 1683-1691Google Scholar
67Nomiyama, T. et al. (2007) Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. Journal of Clinical Investigation 117, 2877-2888CrossRefGoogle ScholarPubMed
68Kiefer, F.W. et al. (2008) Osteopontin expression in human and murine obesity: extensive local up-regulation in adipose tissue but minimal systemic alterations. Endocrinology 149, 1350-1357Google Scholar
69Brown, L.F. et al. (1994) Osteopontin expression and distribution in human carcinomas. American Journal of Pathology 145, 610-623Google Scholar
70Kim, J. et al. (2006) Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. American Journal of Gastroenterology 101, 2051-2059CrossRefGoogle ScholarPubMed
71O'Brien, E.R. et al. (1994) Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arteriosclerosis and Thrombosis 14, 1648-1656Google Scholar
72Speer, M.Y. et al. (2002) Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. Journal of Experimental Medicine 196, 1047-1055CrossRefGoogle ScholarPubMed
73Hirota, S. et al. (1993) Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. A possible association with calcification. American Journal of Pathology 143, 1003-1008Google ScholarPubMed
74Choi, J.S. et al. (2003) Induction and temporal changes of osteopontin mRNA and protein in the brain following systemic lipopolysaccharide injection. Journal of Neuroimmunology 141, 65-73CrossRefGoogle ScholarPubMed
75Iczkiewicz, J., Rose, S. and Jenner, P. (2005) Increased osteopontin expression following intranigral lipopolysaccharide injection in the rat. European Journal of Neuroscience 21, 1911-1920Google Scholar
76Yan, Y.P. et al. (2009) Osteopontin is a mediator of the lateral migration of neuroblasts from the subventricular zone after focal cerebral ischemia. Neurochemistry International 55, 826-832CrossRefGoogle ScholarPubMed
77Fu, Y. et al. (2004) Spinal root avulsion-induced upregulation of osteopontin expression in the adult rat spinal cord. Acta Neuropathologica (Berlin) 107, 8-16CrossRefGoogle ScholarPubMed
78Zhao, C. et al. (2008) Osteopontin is extensively expressed by macrophages following CNS demyelination but has a redundant role in remyelination. Neurobiology of Disease 31, 209-217CrossRefGoogle Scholar
79Harada, K. et al. (2003) Osteopontin is involved in the formation of epithelioid granuloma and bile duct injury in primary biliary cirrhosis. Pathology International 53, 8-17Google Scholar
80Murry, C.E. et al. (1994) Macrophages express osteopontin during repair of myocardial necrosis. American Journal of Pathology 145, 1450-1462Google ScholarPubMed
81Komatsubara, I. et al. (2003) Spatially and temporally different expression of osteonectin and osteopontin in the infarct zone of experimentally induced myocardial infarction in rats. Cardiovascular Pathology 12, 186-194CrossRefGoogle ScholarPubMed
82Szalay, G. et al. (2009) Osteopontin: a fibrosis-related marker molecule in cardiac remodeling of enterovirus myocarditis in the susceptible host. Circulation Research 104, 851-859CrossRefGoogle ScholarPubMed
83Makiishi-Shimobayashi, C. et al. (2004) Localization of osteopontin at calcification sites of cholesteatoma: possible role as a regulator of deposition of calcium phosphate in the middle ear. Auris, Nasus, Larynx 31, 3-9CrossRefGoogle ScholarPubMed
84Hikita, S.T. et al. (2006) Osteopontin is proinflammatory in experimental autoimmune uveitis. Investigative Ophthalmology and Visual Science 47, 4435-4443CrossRefGoogle ScholarPubMed
85Bosco, M.C. et al. (2009) The hypoxic synovial environment regulates expression of vascular endothelial growth factor and osteopontin in juvenile idiopathic arthritis. Journal of Rheumatology 36, 1318-1329CrossRefGoogle ScholarPubMed
86McKee, M.D. and Nanci, A. (1996) Secretion of osteopontin by macrophages and its accumulation at tissue surfaces during wound healing in mineralized tissues: a potential requirement for macrophage adhesion and phagocytosis. Anatomical Record 245, 394-4093.0.CO;2-K>CrossRefGoogle ScholarPubMed
87Mori, R., Shaw, T.J. and Martin, P. (2008) Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring. Journal of Experimental Medicine 205, 43-51Google Scholar
88Nakamura, M. et al. (2002) Osteopontin expression in chronic pancreatitis. Pancreas 25, 182-187CrossRefGoogle ScholarPubMed
89Sato, T. et al. (2005) Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response. Gut 54, 1254-1262CrossRefGoogle ScholarPubMed
90White, F.J. et al. (2006) Secreted phosphoprotein 1 (osteopontin) is expressed by stromal macrophages in cyclic and pregnant endometrium of mice, but is induced by estrogen in luminal epithelium during conceptus attachment for implantation. Reproduction 132, 919-929Google Scholar
91Ophascharoensuk, V. et al. (1998) Role of intrinsic renal cells versus infiltrating cells in glomerular crescent formation. Kidney International 54, 416-425Google Scholar
92Hudkins, K.L. et al. (2000) Osteopontin expression in human crescentic glomerulonephritis. Kidney International 57, 105-116CrossRefGoogle ScholarPubMed
93Hartner, A. et al. (2001) Glomerular osteopontin expression and macrophage infiltration in glomerulosclerosis of DOCA-salt rats. American Journal of Kidney Diseases 38, 153-164CrossRefGoogle ScholarPubMed
94Hudkins, K.L. et al. (2001) Osteopontin expression in human cyclosporine toxicity. Kidney International 60, 635-640Google Scholar
95Cao, Z., Cox, A. and Bonnet, F. (2002) Increased osteopontin expression following renal ablation is attenuated by angiotensin type 1 receptor antagonism. Experimental Nephrology 10, 19-25CrossRefGoogle ScholarPubMed
96Tian, S. et al. (2006) Tubulointerstitial macrophage accumulation is regulated by sequentially expressed osteopontin and macrophage colony-stimulating factor: implication for the role of atorvastatin. Mediators of Inflammation 2006, 12919Google Scholar
97Peng, X. et al. (2006) Detection of osteopontin in the pericyst of human hepatic Echinococcus granulosus. Acta Tropica 100, 163-171Google Scholar
98Nishikaku, A.S. et al. (2009) Nitric oxide participation in granulomatous response induced by Paracoccidioides brasiliensis infection in mice. Medical Microbiology and Immunology 198, 123-135CrossRefGoogle ScholarPubMed
99Smith, L.L. et al. (1998) Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by à 9 á 1 integrin. Journal of Biological Chemistry 271, 28485-28491Google Scholar
100Kazanecki, C.C., Uzwiak, D.J. and Denhardt, D.T. (2007) Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. Journal of Cellular Biochemistry 102, 912-924Google Scholar
101Prieto, J., Eklund, A. and Patarroyo, M. (1994) Regulated expression of integrins and other adhesion molecules during differentiation of monocytes into macrophages. Cellular Immunology 156, 191-211Google Scholar
102Ammon, C. et al. (2000) Comparative analysis of integrin expression on monocyte-derived macrophages and monocyte-derived dendritic cells. Immunology 100, 364-369CrossRefGoogle ScholarPubMed
103Shima, M. et al. (1995) Macrophage-colony-stimulating factor regulates expression of the integrins alpha 4 beta 1 and alpha 5 beta 1 by murine bone marrow macrophages. Proceedings of the National Academy of Sciences of the United States of America 92, 5179-5183CrossRefGoogle ScholarPubMed
104De Nichilo, M.O. and Burns, G.F. (1993) Granulocyte-macrophage and macrophage colony-stimulating factors differentially regulate alpha v integrin expression on cultured human macrophages. Proceedings of the National Academy of Sciences of the United States of America 90, 2517-2521Google Scholar
105Lacy-Hulbert, A. et al. (2007) Ulcerative colitis and autoimmunity induced by loss of myeloid alphav integrins. Proceedings of the National Academy of Sciences of the United States of America 104, 15823-15828CrossRefGoogle ScholarPubMed
106Ashkar, S. et al. (2000) Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287, 860-864Google Scholar
107Potter, M.R. et al. (2002) Role of osteopontin in murine Lyme arthritis and host defense against Borrelia burgdorferi. Infection and Immunity 70, 1372-1381Google Scholar
108Isoda, K. et al. (2003) Osteopontin transgenic mice fed a high-cholesterol diet develop early fatty-streak lesions. Circulation 107, 679-681CrossRefGoogle ScholarPubMed
109Abel, B. et al. (2005) Osteopontin is not required for the development of Th1 responses and viral immunity. Journal of Immunology 175, 6006-6013CrossRefGoogle Scholar
110O'Regan, A.W., Hayden, J.M. and Berman, J.S. (2000) Osteopontin augments CD3-mediated interferon-gamma and CD40 ligand expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells. Journal of Leukocyte Biology 68, 495-502CrossRefGoogle Scholar
111Zhang, S. and Wang, Q. (2008) Factors determining the formation and release of bioactive IL-12: regulatory mechanisms for IL-12p70 synthesis and inhibition. Biochemical and Biophysical Research Communications 372, 509-512CrossRefGoogle ScholarPubMed
112Konno, S. et al. (2005) Endotoxin contamination contributes to the in vitro cytokine-inducing activity of osteopontin preparations. Journal of Interferon and Cytokine Research 25, 277-282Google Scholar
113Aziz, M. et al. (2009) MFG-E8 attenuates intestinal inflammation in murine experimental colitis by modulating osteopontin-dependent {alpha}v{beta}3 integrin signaling. Journal of Immunology 182, 7222-7232Google Scholar
114Shimizu, S. et al. (2010) Osteopontin deficiency impairs wear debris-induced osteolysis via regulation of cytokine secretion from murine macrophages. Arthritis and Rheumatism 62, 1329-1337CrossRefGoogle ScholarPubMed
115Naldini, A. et al. (2006) Cutting edge: IL-1beta mediates the proangiogenic activity of osteopontin-activated human monocytes. Journal of Immunology 177, 4267-4270Google Scholar
116Patarca, R., Saavedra, R.A. and Cantor, H. (1993) Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation 1/ osteopontin gene. Critical Reviews in Immunology 13, 225-246Google ScholarPubMed
117Ono, M., Yamamoto, T. and Nose, M. (1995) Allelic difference in the nucleotide sequence of the Eta-1/Op gene transcript. Molecular Immunology 32, 447-448Google Scholar
118Miyazaki, T. et al. (2005) Implication of allelic polymorphism of osteopontin in the development of lupus nephritis in MRL/lpr mice. European Journal of Immunology 35, 1510-1520Google Scholar
119Gao, C. et al. (2003) Osteopontin inhibits expression of cytochrome c oxidase in RAW 264.7 murine macrophages. Biochemical and Biophysical Research Communications 309, 120-125Google Scholar
120Marroquin, C.E. et al. (2004) Osteopontin increases CD44 expression and cell adhesion in RAW 264.7 murine leukemia cells. Immunology Letters 95, 109-112CrossRefGoogle ScholarPubMed
121Vaschetto, R. et al. (2008) Serum levels of osteopontin are increased in SIRS and sepsis. Intensive Care Medicine 34, 2176-2184CrossRefGoogle ScholarPubMed
122Steitz, S.A. et al. (2002) Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. American Journal of Pathology 161, 2035-2046Google Scholar
123Rollo, E.E., Laskin, D.L. and Denhardt, D.T. (1996) Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW 264.7 macrophages. Journal of Leukocyte Biology 60, 397-404Google Scholar
124Tian, J.Y. et al. (2000) Regulation of NO synthesis induced by inflammatory mdiators in RAW264.7 cells: collagen prevents inhibition by osteopontin. Cytokine 12, 450-457Google Scholar
125Gao, C. et al. (2007) Osteopontin induces ubiquitin-dependent degradation of STAT1 in RAW264.7 murine macrophages. Journal of Immunology 178, 1870-1881CrossRefGoogle ScholarPubMed
126Guo, H. et al. (2008) Osteopontin mediates Stat1 degradation to inhibit iNOS transcription in a cecal ligation and puncture model of sepsis. Surgery 144, 182-188Google Scholar
127Bourassa, B., Monaghan, S. and Rittling, S.R. (2004) Impaired anti-tumor cytotoxicity of macrophages from osteopontin-deficient mice. Cellular Immunology 227, 1-11Google Scholar
128Heilmann, K. et al. (2009) Osteopontin as two-sided mediator of intestinal inflammation. Journal of Cellular and Molecular Medicine 13, 1162-1174Google Scholar
129Nau, G.J. et al. (1999) Attenuated host resistance against Mycobacterium bovis BCG infection in mice lacking osteopontin. Infection and Immunity 67, 4223-4230Google Scholar
130Pedraza, C.E. et al. (2008) Osteopontin functions as an opsonin and facilitates phagocytosis by macrophages of hydroxyapatite-coated microspheres: implications for bone wound healing. Bone 43, 708-716CrossRefGoogle ScholarPubMed
131Singh, R.P. et al. (1990) Definition of a specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and murine macrophages in vitro and its effect upon macrophages in vivo. Journal of Experimental Medicine 171, 1931-1942CrossRefGoogle Scholar
132Giachelli, C.M. et al. (1998) Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. American Journal of Pathology 152, 353-358Google Scholar
133Marcondes, M.C. et al. (2008) In vivo osteopontin-induced macrophage accumulation is dependent on CD44 expression. Cellular Immunology 254, 56-62Google Scholar
134Bruemmer, D. et al. (2003) Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. Journal of Clinical Investigation 112, 1318-1331Google Scholar
135Duvall, C.L. et al. (2008) The role of osteopontin in recovery from hind limb ischemia. Arteriosclerosis, Thrombosis, and Vascular Biology 28, 290-295CrossRefGoogle ScholarPubMed
136Nystrom, T., Duner, P. and Hultgardh-Nilsson, A. (2007) A constitutive endogenous osteopontin production is important for macrophage function and differentiation. Experimental Cell Research 313, 1149-1160CrossRefGoogle ScholarPubMed
137Panzer, U. et al. (2001) Monocyte chemoattractant protein-1 and osteopontin differentially regulate monocytes recruitment in experimental glomerulonephritis. Kidney International 59, 1762-1769CrossRefGoogle ScholarPubMed
138Okada, H. et al. (2000) Osteopontin expressed by renal tubular epithelium mediates interstitial monocyte infiltration in rats. American Journal of Physiology. Renal Physiology 278, F110-F121Google Scholar
139Mazzali, M. et al. (2002) Effects of cyclosporine in osteopontin null mice. Kidney International 62, 78-85CrossRefGoogle ScholarPubMed
140Ophascharoensuk, V. et al. (1999) Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney International 56, 571-580Google Scholar
141Yoo, K.H. et al. (2006) Osteopontin regulates renal apoptosis and interstitial fibrosis in neonatal chronic unilateral ureteral obstruction. Kidney International 70, 1735-1741CrossRefGoogle ScholarPubMed
142Persy, V.P. et al. (2003) Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice. Kidney International 63, 543-553Google Scholar
143Wolak, T. et al. (2009) Osteopontin modulates angiotensin II-induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney International 76, 32-43CrossRefGoogle ScholarPubMed
144Morimoto, J. et al. (2004) Osteopontin affects the persistence of beta-glucan-induced hepatic granuloma formation and tissue injury through two distinct mechanisms. International Immunology 16, 477-488Google Scholar
145O'Regan, A.W. et al. (2001) Abnormal pulmonary granuloma formation in osteopontin-deficient mice. American Journal of Respiratory and Critical Care Medicine 164, 2243-2247Google Scholar
146Crawford, H.C., Matrisian, L.M. and Liaw, L. (1998) Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Research 58, 5206-5215Google ScholarPubMed
147Feng, F. and Rittling, S.R. (2000) Mammary tumor development in MMTV-c-myc/MMTV-v-Ha-ras transgenic mice is unaffected by osteopontin deficiency. Breast Cancer Research and Treatment 63, 71-79Google Scholar
148Cheng, J. et al. (2007) Human macrophages promote the motility and invasiveness of osteopontin-knockdown tumor cells. Cancer Research 67, 5141-5147CrossRefGoogle ScholarPubMed
149Kiefer, F.W. et al. (2010) Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes 59, 935-946Google Scholar
150Kwon, H.J. et al. (2010) The role of osteopontin in d-galactosamine-induced liver injury in genetically obese mice. Toxicology and Applied Pharmacology 242, 344-351Google Scholar
151da Silva, A.P. et al. (2009) Osteopontin attenuation of dextran sulfate sodium-induced colitis in mice. Lab Investigation 89, 1169-1181CrossRefGoogle ScholarPubMed
152da Silva, A.P. et al. (2006) Exacerbated tissue destruction in DSS-induced acute colitis of OPN-null mice is associated with downregulation of TNF-alpha expression and non-programmed cell death. Journal of Cellular Physiology 208, 629-639CrossRefGoogle ScholarPubMed
153Zhong, J. et al. (2006) Osteopontin deficiency protects mice from Dextran sodium sulfate-induced colitis. Inflammatory Bowel Diseases 12, 790-796CrossRefGoogle ScholarPubMed

Further reading, resources and contacts

Information about past and present conferences focused on OPN, as well as other information about the protein, can be found at the 2010 FASEB osteopontin conference website:

Sodek, J., Ganss, B. and McKee, M.D. (2000) Osteopontin. Critical Reviews in Oral Biology and Medicine 11, 279-303CrossRefGoogle ScholarPubMed
Ramaiah, S.K. and Rittling, S. (2007) Pathophysiological role of osteopontin in hepatic inflammation, toxicity and cancer. Toxicological Sciences 103, 4-13Google Scholar
Dale, D.C., Boxer, L. and Liles, W.C. (2008) The phagocytes: neutrophils and monocytes. Blood 112, 935-945Google Scholar
Geissmann, F. et al. (2010) Development of monocytes, macrophages, and dendritic cells. Science 327, 656-661CrossRefGoogle ScholarPubMed
Sodek, J., Ganss, B. and McKee, M.D. (2000) Osteopontin. Critical Reviews in Oral Biology and Medicine 11, 279-303CrossRefGoogle ScholarPubMed
Ramaiah, S.K. and Rittling, S. (2007) Pathophysiological role of osteopontin in hepatic inflammation, toxicity and cancer. Toxicological Sciences 103, 4-13Google Scholar
Dale, D.C., Boxer, L. and Liles, W.C. (2008) The phagocytes: neutrophils and monocytes. Blood 112, 935-945Google Scholar
Geissmann, F. et al. (2010) Development of monocytes, macrophages, and dendritic cells. Science 327, 656-661CrossRefGoogle ScholarPubMed
Figure 0

Figure 1. Key features of mouse osteopontin protein. The unstructured nature of the molecule is indicated by the blue line. The central integrin-binding sequences of mouse osteopontin are indicated: the RGD sequence is underlined in teal, and the SLAYGLR sequence is depicted in purple. The specific integrins that bind to each of these two sequences are indicated. Other features of the molecule are identified: heparin-binding sequences and the poly-Asp sequence that mediates binding to hydroxyapatite (Ref. 9); O-glycosylation sites and a subset of phosphorylation sites (Ref. 10); sites of cleavage by thrombin and matrix metalloproteinase (MMP); and recently identified N-terminal sequences involved in lymphocyte binding (Ref. 11) and induction of chemokine expression (Ref. 12). The binding sequence mediating CD44 interaction is controversial (see text).

Figure 1

Figure 2. Summary of osteopontin regulation in and effects on monocytes and macrophages. Substances that induce osteopontin (OPN) expression in monocytes (left) and macrophages (right) are indicated in the blue boxes. Phorbol myristate acetate (PMA) induces both OPN expression and differentiation of monocytes into macrophages. The presence of intracellular OPN in macrophages is indicated. Some effects of OPN on macrophage function are listed in the pink box; although these are depicted as resulting from OPN secreted by macrophages (curved arrow), the protein could also be secreted by nearby cells. Note that the effect of OPN on reactive nitrogen intermediates (RNIs) and reactive oxygen intermediates (ROIs) is suppressive. Abbreviations: CSF, colony-stimulating factor; IFN, interferon; IL, interleukin; LPS, lipopolysaccharide; TNF, tumour necrosis factor.

Figure 2

Table 1. Osteopontin expression in macrophages in vivo

Figure 3

Table 2. Effect of osteopontin on macrophage accumulation in renal injury